Upload
ge-healthcare-life-sciences
View
464
Download
0
Embed Size (px)
Citation preview
Imagination at work
Case studies on using manufacturing platforms for mAbs, recombinant proteins, and vaccinesPatrick GuertinGlobal Technical Manager Biomanufacturing Services, GE HealthcarePresented at BPI East, October 6, 2016
Fast Trak your molecule to market
Fast Trak services: rapid market access with total transparency
Cell culture media & supplements
Upstream PD
Downstream PD
Clinical manufacturing
Analytical development/quality control
Process transfer
Training & education
• Medium and feed development and optimization • Rapid Response Production prototypes• Spent medium analysis
• Full upstream process development • Conversion from stainless to single-use cequipment • Scale-up and proof of concept • Bioreactor process optimization • Design of experiments (DoE)
• Full downstream process development • Conversion: stainless to single-use • High-throughput process development • Resin CIP studies • Resin lifetime studies • Design of experiments (DoE) • Viral clearance studies • Scale-up and proof of concept
• Phase I & II manufacturing: 10–2000 L • BSL2 production: 10–500 L • cGMP solution and buffer preparation • cGMP document preparation • Environmental monitoring • cGMP inspection, sampling, release of materials • Quality assurance guidance and oversight
• Method developments• Method transfers • Method qualifications • Reference standard characterization • Stability studies • cGMP lot release testing
• Incoming and outgoing process transfer at any stage • Customer process training • Process documentation • Process gap analysis (site and equipment) • Person in plant (PiP) support • Test methods • Bill of materials
• Standard & custom courses in biologic drug development and manufacturing • Customer on-site access and transparency during all production batches • Hands-on training and education • Process documentation • PiP support
2
PD- process developmentCIP- cleaning in placeBSL2- biosafety level 2cGMP- current good manufacturing
Fast Trak experience
> 300 years of collective industry experience (Biomanufacturing Leadership Team)> 100 production campaigns completed> 17 different expression systems utilized> 17 virus clearance studies completed
All projects were converted from conventional to single-use technologies.
Monoclonal antibodies Viruses
Virus -like particles
Fusion proteins Hormones Enzymes
3
In the pursuit of developing innovative therapeutics, biopharmaceutical companies are challenged with:
Risk reduction Drive for cost reduction Aggressive timelines Speed to market
4
Case study 1: Biosimilar mAbs, an emerging marketCustomer success through working with global service and technology provider focused on:
Building strong relationships Streamlining technology transfer strategies Single-use technologies Flexible and deployable manufacturing platforms
29230903AA I October 2016
Customer success storySupport of a biopharma customer in reducing risk and increasing speed to market of their target molecules, while working under aggressive timelines
CUSTOMER NEEDS• Design scope of work• Convert from conventional to single-use technologies• Scale-up from 10 L to 200 L, with ultimate target of
2000 L, bioreactor for two biosimilar mAb molecules• Deploy a global, flexible, scalable, cost-effective
biosimilar manufacturing platform under aggressive timelines
• Be first to market in emerging regions• Process transfer to customer’s site in emerging region
CUSTOMER CONCERNS• Aggressive timelines: completion of work in less than
six months• Molecule biosimilarity comparison after process
transfer to single-use technology• Process and equipment design• Protection of customers intellectual property (IP) • Communication with and alignment of global teams• Real-time scope/process changes and definition
phase progressed
29230903AA I October 2016
Project scope of work
4 × 10 L runs Process
transfer Generation of• protocols• solution
records• bill of materials
Initial scope Another set of 10
L runs were performed
Process transfer Generation of• protocols• solution records• bill of materials
Process confirmation
Scale-up 4 × 200 L runs Generation of• protocols• solution records• bill of materials
Proof of concept
Process scaled from a vial to complete purification of two biosimilar mAb molecules
with the goal to manufacture at 2000 L scale
29230903AA I October 2016
Technical transfer and conversion to single-use equipment
Upstream process Downstream process
Critical parameters:Seed train, agitation rates, pH, dissolved O2 , sparge pore size, feed, gassing, and bioreactor control strategies.
Critical parameters:Velocities, resin binding capacities, collection criteria, flux rates, temperatures, pressures, pH, conductivity, hold times, storage conditions.
29230903AA I October 2016
Product A & B: upstream process resultsProduct A 10 L confirmation
run200 L run 1 200 L run 2
Maximum cell density
17× 106 M cells/mL 24 × 106 M Cells/mL 20 × 106 M Cells/mL
Product titer 2.4 mg/mL 3.3 mg/mL 3.2 mg/mLComparable to client data
Low but acceptable Yes Yes
Product biosimilarity confirmation
Confirmed by client Confirmed by client Confirmed by client
Product B 10 L confirmation run
200 L run 1 200 L run 2
Maximum cell density
11 ×106 M cells/mL 10 × 106 M cells/mL 11 × 106 M cells/mL
Product titer 3.4 mg/mL 3.4 mg/mL 3.9 mg/mLComparable to client data
Yes Yes Yes
Product biosimilarity confirmation
Confirmed by client Confirmed by client Confirmed by client
929230903AA I October 2016
Product A: downstream process results
Product A 10 L confirmation run
Step recovery
200 L run 1Step recovery
200 L run 2Step recovery
Clarification 86% 88% 88%Protein A +VI 93% 102% 91%Anion exchange 89% 86% 99%UFDF 95% 98% 97%Total process recovery
68% 76% 73%
Comparable to client data
Yes Yes Yes
Product biosimilarity comparison
Confirmed by client Confirmed by client Confirmed by client
10UFDF = ultrafiltration/diafiltration29230903AA I October 2016
Product B: downstream process results
Product B 10 L confirmation run
Step recovery
200 L run 1Step recovery
200 L run 2Step recovery
Clarification 84% 85% 93%Protein A +VI 114% 98% 95%Anion exchange 93% 86% 93%Cation exchange 73% 78% 79%UFDF 95% 94% 96%Total process recovery
62% 53% 65%
Comparable to client data
Yes Yes Yes
Product biosimilarity comparison
Confirmed by client Confirmed by client Confirmed by client
11UFDF = ultrafiltration/diafiltration29230903 AA I October 2016
Process transfer to customer siteLocal Fast Trak services teams support process transfer to emerging regions, sourcing of local raw materials, and understand local government and regulatory requirements
FlexFactory™ platformKUBio™ facilityContract manufacturerCustomer facility
At GE
FAST TRAK MANUFACTURING SERVICES
Process developmentAnalytical developmentScale-up
Documentation preparationcGMP manufacturingTrain/educate customer team
TransPlant
PROCESS DOCUMENTATION TRAINING START-UPANALYTICAL
12
cGMP = current good manufacturing practices
Process transfer to customer siteFast Trak Asia and US teams collaborating/training during the 200 L
production batches
Marlborough, MA, U.S.A.
Logan, UT, U.S.A.
Uppsala, Sweden
Istanbul, Turkey Seoul, S. KoreaShanghai,
ChinaTokyo, Japan
Singapore
Bangalore, India
Project outcomes
Conversion from conventional to single-use technology and scale-up from 10 L to 200 L
Project completed in 5 months (incl. completion of 6 × 10 L batches, 4 × 200 L batches, generation of > 50 process documents, and 4 complete bills of materials.
Customer internal timeline for similar scope of work was estimated to 18 months.
Black box approach to protect customer’s intellectual property (IP) (initially, culture media and feeds, several process solutions, and biosimilarity analytics were unknown).
Succeeded in titer requirement of 3–4 g/L.
Product met biosimilarity requirements.14
KUBio™ manufacturing facilityThe KUBio facility is our turnkey cGMP-compliant process solution for mAbproduction. The modular units are factory-built, final assembly on customer site. Because different parts are developed concurrently, your KUBio facility is fully operational in just 18 to 24 months.
Assembled on brown or greenfield site
Built, assembled, qualified, and ready-to-run within 18 to 24 months
Includes FlexFactory™ single-use platform
2 × 500 L to 4 × 2000 L facilities Segregated up- and downstream
operations, including gowning
15cGMP = current good manufacturing practices
GE Healthcare’s Fast Trak services enable customer outcomes
16
Expe
rtis
e
Single-use technologyProcess developmentAnalytical developmentProcess scale-upcGMP manufacturingProject managementTraining & education
Tim
eExperience and expertise to get it right the first timeCross- functional teamsProven technical transfer and quality systems
Flex
ibili
ty
End-to-end services to choose fromTransplant services to customer site with full support
Risk
re
duct
ion
Guidance and oversight from experienced teams
Tran
spar
enc y
Full customer transparencyCustomer actively involved in projectCustomer access to development space
Glo
bal
reac
h
GE’s facilities located all over the worldReach into product and equipment specialistsReach into GE’s global operations
cGMP = current good manufacturing practices
29230903AA I October 2016
GE, Imagination at work, GE monogram, HyClone, KUBio, FlexFactory, ÄKTA, BioProcess, Cytodex, ReadyCircuit, ReadyMate, ReadyToProcess, ReadyToProcess WAVE, and Xcellerex are trademarks of General Electric Company. ReadyMate is covered by US patent number 6,679,529 B2 owned by Johnson and Boley Holdings, LLC and licensed to GE Healthcare companies. OptiPRO is a trademark of Life Technologies. All other third party trademarks are the property of their respective owners.© 2016 General Electric Company. First published Oct. 2016.GE Healthcare UK Ltd., Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UKGE Healthcare Europe GmbH, Munzinger Strasse 5, D-79111 Freiburg, GermanyGE Healthcare Bio-Sciences Corp., 100 Results Way, Marlborough, MA 01752, USAGE Healthcare Dharmacon Inc., 2650 Crescent Dr, Lafayette, CO 80026, USAHyClone Laboratories Inc., 925 W 1800 S, Logan, UT 84321, USAGE Healthcare Japan Corp., Sanken Bldg., 3-25-1, Hyakunincho Shinjuku-ku, Tokyo 169-0073, JapanAll goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.For local office contact information, visit www.gelifesciences.com/contact www.gelifesciences.com
GE Healthcare Bio-Sciences ABBjörkgatan 30751 84 UppsalaSweden
29230903AA I October 2016
29230903 AA I October 2016
Medium preparation: XcellerexTM XDUO 100 to 2500 L mixers, HyCloneTM cell culture media
Buffer preparation: Xcellerex XDUO 100 to 2500 L mixers, HyClone buffers and process liquids
Cell culture seed train ReadyToProcess WAVETM 25 systemXcellerex XDR 200 L bioreactorXcellerex XDR 500 L bioreactor
Cell culture production Xcellerex XDR 2000 L bioreactorReadyToProcessTM filter for CFF
Harvestoperations FlexFactoryTM harvestBioProcessTM NFF Pump System
Virus reduction Xcellerex XDUO mixers
Purification operations ÄKTATM ready systemReadyToProcess chromatography columnReadyToProcess filter for CFF
Virus filtration FlexFactory viral clearanceBioProcess NFF Pump System
Bulk formulation and sterile filtration Bulk fill equipment
Fluid management ReadyToProcess portfolioReadyCircuitTM bag and filter assembliesReadyToProcess bins and ReadyCircuit bagsReadyMateTM aseptic connectors
Fast Trak Services Process developmentBridge Manufacturing ServicesTraining and education